Patent intelligence · US
US 9526765
Delivery of therapeutic agents by a collagen binding protein
Delivery of therapeutic agents by a collagen binding protein
Patent details — US 9526765
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 27, 2016
- Expiration
- Dec 22, 2036
- Applicant
- Montefiore Medical Center
- Claims
- 12
- CPC classes
- A61K, A61K38/29, A61K38/48, A61K47/56
Quick answer
US 9526765 (Delivery of therapeutic agents by a collagen binding protein) is held by Montefiore Medical Center. Status: granted. Granted Dec 27, 2016. Expires Dec 22, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Montefiore Medical Center
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K38/29, A61K38/48, A61K47/56, A61K47/64, A61P
More from Montefiore Medical Center
Related pharmaceutical patents in our USPTO index.
-
US 12391663
Isoindolinone compounds
granted -
US 12378199
Rigidified pentadentate chelating agents useful for the [Al18F]2+ labelling of biomolecules
granted -
US 12280029
Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
granted -
US 12263143
Ionic channel modulation as a method for treating tumors through inflammasome activation
granted -
US 12257247
Targeted degradation of VAV1
granted -
US 12214218
Perfusion modulated tumor dose sculpting with single dose radiotherapy
granted -
US 12070628
Low energy immune priming for treating cancer and metastasis
granted -
US 12011619
Low intensity focused ultrasound for treating cancer and metastasis
granted
Frequently asked questions
What is US patent 9526765?
US 9526765 (Delivery of therapeutic agents by a collagen binding protein) is held by Montefiore Medical Center. Status: granted. Granted Dec 27, 2016. Expires Dec 22, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9526765?
Montefiore Medical Center is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 72 pharmaceutical patents for this assignee.
When does US 9526765 expire?
Our index shows an expiration date of Dec 22, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.